Definitive Contract W911SR21C5049
Award Date
9/30/21
Potential Completion Date
11/10/23
Potential Value
$1.1M
Funding Federal Agency
Joint PEO Chemical and Biological Defense
Contracting Federal Agency
ACC Aberdeen Proving Ground
Awardee
Arisan Therapeutics Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Set-Aside Type
Total Small Business
Federal Contract Vehicle
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92121, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase II Action
Primary Consortia Member
Not listed
Similar Awards
This is a $96,111.02 firm fixed-price Purchase Order awarded to Arisan Therapeutics Inc., a small disadvantaged business, by the Joint Program Executive Office for Chemical and Biological Defense, a component of the U.S. Department of Defense. The contract is for the principal investigator to conduct SBIR Program Phase I research and development, which is a total small business set-aside. Arisan Therapeutics is a small business that provides research and development services to federal agencies,...
This is a $526,793.52 Firm Fixed Price SBIR Phase II contract awarded by the Joint PEO Chemical and Biological Defense to Arisan Therapeutics Inc., a small disadvantaged business. The contract is for research and development services supporting the development of countermeasures against chemical and biological threats. This contract is a follow-on to previous SBIR Phase I and II awards to Arisan Therapeutics totaling over $790,000. The company has also received other federal research contracts...
This federal contract award, valued at $330,136,246.14, was granted by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services, to 4J Therapeutics Inc., a self-certified small disadvantaged business. The contract's objective is to demonstrate the versatility and efficacy of 4J Therapeutics' programmable antiviral technology platform by assembling a preclinical package for LNA14, performing a Phase 1a...
This is a $3,007,557.97 definitive contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Autonomous Therapeutics Inc., a small business biotechnology company. The contract is for the development of new platform technologies for viral and therapeutic evolution assays under DARPA's Small Business Innovation Research (SBIR) Program Phase II. The contract has a firm fixed price pricing type and a period of performance through November 2022. Autonomous Therapeutics has also...
<p>This is a Definitive Contract awarded by the Office of Research and Development, a civilian agency within the U.S. federal government, to Anfiro, Inc., a small business. The contract, valued at $99,999.90, is for Anfiro's SBIR Phase I research and development efforts. It was awarded on May 1, 2019 and has a period of performance through October 31, 2019. The contract is a Firm Fixed Price arrangement. This award is designated as a Total Small Business set-aside.</p>
The Department of the Army Medical Command awarded Ophirex, Inc. a $10.6 million definitive contract to support research and development efforts for a COVID-19 treatment under the Small Business Innovation Research Program Phase III. The prime contractor will conduct work at its place of performance in Corte Madera, California from June 2020 through September 2023 under the firm fixed price contract, which has a total small business set aside designation. Specifically, Ophirex will perform...
This $1,797,717.00 Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the National Institutes of Health (NIH), to Intralytix Inc., a biotechnology company specializing in bacteriophage-based products. The contract is for the development of a "Universal, Scalable Artificial Intelligence-Based Platform for Manufacturing High Titer Biopharmaceuticals", which aligns with...
This federal contract award is an Army SBIR Phase I contract valued at $167,421.12, awarded to Consegna Pharma Inc., a small disadvantaged business. The contract is for pharmaceutical research and development services focused on reformulating drugs to create improved treatments, with a focus on chemical and biological defense. Consegna has also received other federal contracts and grants, including a $1,099,999 Army SBIR Phase II contract and grants from the National Institute on Drug Abuse...
This $18,274,778 definitive contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to AN2 Therapeutics, Inc. The contract supports the development of epetraborole as a novel therapeutic for melioidosis and additional antimicrobial resistant bacterial biothreat pathogens. This award was issued under a Broad Agency Announcement (BAA) that also sought proposals for advanced vaccine and diagnostic development against biodefense and emerging...
This is a $3,247,731 definitive contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Autonomous Therapeutics Inc., a small business biotechnology company. The contract is for the development of a first-in-human therapeutic interfering particle targeting a respiratory virus, under DARPA's research programs. Autonomous Therapeutics has also been awarded an Indefinite Delivery Vehicle (IDV) by DARPA, with a potential value of $4,579,822, to develop and deliver therapeutic...